A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Status: Recruiting
Location: See all (71) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Have a primary Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revised (DSM-5-TR) diagnosis of MDD without psychotic features confirmed by Structured Clinical Interview for DSM 5 Disorders, Clinical Trials Version (SCID 5 CT) at screening (this may be a first or recurrent episode).

• Participant's current major depressive episode must be confirmed by independent assessment.

• The symptoms of the current MDD episode have been present for more than 4 weeks prior to the Screening Visit, but no longer than 12 months prior to the Screening Visit.

• Have a MADRS total score of 25 or higher at Screening and Baseline.

• A change in MADRS total score between Screening and Baseline of ≤20%.

Locations
United States
California
Neumora Investigator Site
RECRUITING
Encino
Neumora Investigator Site
RECRUITING
Garden Grove
Neumora Investigator Site
COMPLETED
Los Alamitos
Neumora Investigator Site
RECRUITING
Newport Beach
Neumora Investigator Site
RECRUITING
Orange
Neumora Investigator Site
ACTIVE_NOT_RECRUITING
Santa Ana
Connecticut
Neumora Investigator Site
ACTIVE_NOT_RECRUITING
Norwalk
Florida
Neumora Investigator Site
RECRUITING
Bradenton
Neumora Investigator Site
COMPLETED
Homestead
Neumora Investigator Site
COMPLETED
Lauderhill
Neumora Investigator Site
RECRUITING
Maitland
Neumora Investigator Site
RECRUITING
Miami
Neumora Investigator Site
RECRUITING
Miami
Neumora Investigator Site
RECRUITING
Miami
Neumora Investigator Site
ACTIVE_NOT_RECRUITING
Miami
Neumora Investigator Sites
RECRUITING
Miami
Neumora Investigator Site
RECRUITING
Miami Lakes
Neumora Investigator Site
ACTIVE_NOT_RECRUITING
Miami Lakes
Neumora Investigator Site
RECRUITING
Orlando
Neumora Investigator Site
RECRUITING
Orlando
Neumora Investigator Site
RECRUITING
Orlando
Neumora Investigator Site
COMPLETED
Pinellas Park
Neumora Investigator Site
RECRUITING
Pompano Beach
Neumora Investigator Site
RECRUITING
Tampa
Neumora Investigator Site
RECRUITING
Tampa
Neumora Investigator Site#1
RECRUITING
Tampa
Georgia
Neumora Investigator Site
COMPLETED
Atlanta
Neumora Investigator Site
RECRUITING
Atlanta
Neumora Investigator Site
RECRUITING
Atlanta
Louisiana
Neumora Investigator Site
COMPLETED
Marrero
Neumora Investigator Site
RECRUITING
New Orleans
Massachusetts
Neumora Investigator Site
RECRUITING
Boston
Neumora Investigator Site
ACTIVE_NOT_RECRUITING
Watertown
Maryland
Neumora Investigator Site
RECRUITING
Baltimore
Neumora Investigator Site
RECRUITING
Towson
Minnesota
Neumora Investigator Site
RECRUITING
Mankato
North Carolina
Neumora Investigator Site
ACTIVE_NOT_RECRUITING
Monroe
New Jersey
Neumora Investigator Site
RECRUITING
Princeton
Neumora Investigator Site
RECRUITING
Toms River
New Mexico
Neumora Investigator Site
RECRUITING
Albuquerque
New York
Neumora Investigator Site
RECRUITING
Buffalo
Neumora Investigator Site
RECRUITING
Inwood
Neumora Investigator Site
ACTIVE_NOT_RECRUITING
New York
Neumora Investigator Site
RECRUITING
The Bronx
Ohio
Neumora Investigator Site
ACTIVE_NOT_RECRUITING
North Canton
Oklahoma
Neumora Investigator site
RECRUITING
Edmond
Neumora Investigator Site
RECRUITING
Oklahoma City
South Carolina
Neumora Investigator Site
COMPLETED
North Charleston
Tennessee
Neumora Investigator Site
RECRUITING
Memphis
Texas
Neumora Investigator Site
RECRUITING
Austin
Neumora Investigator Site
RECRUITING
Dallas
Neumora Investigator Site
RECRUITING
Houston
Washington
Neumora Investigator Site
RECRUITING
Bellevue
Neumora Investigator Site
RECRUITING
Everett
Other Locations
Brazil
Neumora Investigator Site
RECRUITING
Curitaba
Neumora Investigator Site
RECRUITING
Porto Alegre
Neumora Investigator Site
RECRUITING
Rio De Janeiro
Neumora Investigator Site
RECRUITING
Santa Cecília
Neumora Investigator Site
RECRUITING
São Bernardo Do Campo
Neumora Investigator Site
RECRUITING
São José Do Rio Preto
Neumora Investigator Site
RECRUITING
São Paulo
Canada
Neumora Investigator Site
RECRUITING
Hamilton
Neumora Investigator Site
RECRUITING
Kelowna
Neumora Investigator site
ACTIVE_NOT_RECRUITING
Markham
Neumora Investigator Site
ACTIVE_NOT_RECRUITING
Toronto
Neumora Investigator Site
ACTIVE_NOT_RECRUITING
Toronto
Chile
Neumora Investigator Site
RECRUITING
Antofagasta
Neumora Investigator Site
RECRUITING
Santiago
Neumora Investigator Site
RECRUITING
Santiago
Neumora Investigator Site
ACTIVE_NOT_RECRUITING
Santiago
Neumora Investigator Site
RECRUITING
Santiago
Contact Information
Primary
Study Contact
explore@koastalstudy.com
Time Frame
Start Date: 2023-12-20
Estimated Completion Date: 2026-06
Participants
Target number of participants: 332
Treatments
Experimental: NMRA-335140 80 milligrams (mg) once daily (QD)
Participants will receive a NMRA- 335140 tablet at a dose of 80 mg once daily (QD)
Placebo_comparator: Placebo
Placebo participants will receive matching placebo tablet once daily.
Related Therapeutic Areas
Sponsors
Leads: Neumora Therapeutics, Inc.

This content was sourced from clinicaltrials.gov